Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy and safety of Anlotinib in combination with
STUPP regimen for MGMT promoter nonmethylated glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University